STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia - The Lancet Oncology
BCR-ABL signaling mimics growth factor activation. Growth factors are... | Download Scientific Diagram
The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL | IntechOpen
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface* - Journal of Biological Chemistry
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer - Oliver Hantschel, 2012
Figure 1 from STI571: targeting BCR-ABL as therapy for CML. | Semantic Scholar
JCI - Applying the discovery of the Philadelphia chromosome
Mechanism of action of BCR (breakpoint cluster region)-ABL (Abelson 1... | Download Scientific Diagram
Regulation of the c-Abl and Bcr–Abl tyrosine kinases | Nature Reviews Molecular Cell Biology
The tyrosine kinase c-Abl potentiates interferon-mediated antiviral immunity by STAT1 phosphorylation - ScienceDirect
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. - Australian Medical Student Journal
BCR-ABL1 and the Philadelphia chromosome - Part 3: The BCR-ABL fusion protein - YouTube
Bcr-Abl阻害 | Bcr-Abl Inhibition
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade | Cell Communication and Signaling | Full Text
IJMS | Free Full-Text | The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
Structure and Dynamic Regulation of Abl Kinases* - ScienceDirect
Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia | NEJM
Flying under the radar: the new wave of BCR–ABL inhibitors | Nature Reviews Drug Discovery
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia - The Lancet
